Compumedics (ASX:CMP): Expecting $70m sales but trading at barely over 1x Revenues, is this a buy?

Some investors may think Compumedics (ASX:CMP) is highly undervalued. It trades at $75m, a level that many clinical-stage medtech or biotech stocks are trading well above…but Compumedics is a commercial-stage company expecting nearly that amount of sales for an entire year.

Read the full ‘Stocks Down Under’ report by Nick Sundich highlighting the outstanding value of Compumedics Limited at the current share price –

Click here to read the Report